Antiviral Activity of AZD7295 in HCV Carriers

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

PK, safety study of AZD7295 in HCV carriers

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Arrow Therapeutics
• Treatments: Antiviral Agents

Criteria

Inclusion Criteria:

• HCV carrier

Exclusion Criteria:

• concurrent medications